Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.
Simple Summary: In metastatic NSCLC with high PD-L1 expression, about one-third of patients treated with pembrolizumab develop immune-related thyroid dysfunction (irTD). Our study of 363 patients shows that those who experience irTD have significantly longer progression-free survival compared to tho...
| Publicado en: | Current Oncology Vol. 31; no. 2; pp. 109 - 122 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Feb2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |